3D Printing Biotech Company Announces Positive Results For Fatty Liver Disease Treatment
Breakthrough in MASH Treatment: Organovo's FXR314 Shows Promising Phase 2 Results
In a significant step forward for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Organovo Holdings Inc. has announced positive Phase 2 trial results for its experimental drug, FXR314. This development marks a pivotal moment in the fight against MASH, a severe form of fatty liver disease that poses a substantial health risk to millions worldwide. $Organovo Holdings (ONVO.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
